Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443820 in ALS – Phase II
CTR20221567Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing SAR443820 with Placebo (2 arms). Started Jun 2022; status: terminated.
02
Drugs
oditrasertib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on CTR20221567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221567.